GSK’s China Woes Offer ‘Teachable Moment’ for Other Drugmakers

As senior officials of GlaxoSmithKline (GSK) face accusations of bribing Chinese government officials, experts on the U.S. Foreign Corrupt Practices Act say the case offers a cautionary tale on how to conduct — or not conduct — business in a foreign market. The alleged kickbacks — described by the Ministry of Public Security as “serious economic crimes” — were given to government officials, medical associations, hospitals and doctors in the cities of Changsha, Shanghai and Zhengzhou, and were aimed at increasing sales and prices of GSK drugs, the ministry said.
International Pharmaceutical Regulatory Monitor